Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.

2.

Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML.

Hyo Kim L, Sub Cheong H, Koh Y, Ahn KS, Lee C, Kim HL, Doo Shin H, Yoon SS.

J Hum Genet. 2015 Dec;60(12):749-54. doi: 10.1038/jhg.2015.105. Epub 2015 Sep 10.

PMID:
26354033
3.

FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.

Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F.

Blood. 2003 Oct 1;102(7):2387-94. Epub 2003 Jun 19.

4.

RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.

Abraham A, Varatharajan S, Karathedath S, Philip C, Lakshmi KM, Jayavelu AK, Mohanan E, Janet NB, Srivastava VM, Shaji RV, Zhang W, Abraham A, Viswabandya A, George B, Chandy M, Srivastava A, Mathews V, Balasubramanian P.

Pharmacogenomics. 2015 Jul;16(8):877-90. doi: 10.2217/pgs.15.44. Epub 2015 Jun 17.

5.

SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.

Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G, Schaich M.

Leukemia. 2009 Oct;23(10):1929-32. doi: 10.1038/leu.2009.113. Epub 2009 May 21. No abstract available.

PMID:
19458626
6.

The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.

Galmarini CM, Cros E, Thomas X, Jordheim L, Dumontet C.

Haematologica. 2005 Dec;90(12):1699-701.

7.

Potential mechanisms of resistance to cytarabine in AML patients.

Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C.

Leuk Res. 2002 Jul;26(7):621-9.

PMID:
12008078
8.

Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.

Xu PP, Chen BA, Feng JF, Cheng L, Xia GH, Li YF, Qian J, Ding JH, Lu ZH, Wang XM, Xu K, Schultz M.

Chin Med J (Engl). 2012 Jun;125(12):2137-43.

PMID:
22884143
9.

Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype.

Jakobsen Falk I, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Br J Haematol. 2014 Dec;167(5):671-80. doi: 10.1111/bjh.13097. Epub 2014 Aug 23.

10.

Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.

Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.

Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.

PMID:
28318150
12.

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.

How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM.

Cancer. 2012 Dec 15;118(24):6110-7. doi: 10.1002/cncr.27683. Epub 2012 Jun 26.

14.

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.

Estey EH.

Am J Hematol. 2012 Jan;87(1):89-99. doi: 10.1002/ajh.22246.

15.

Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.

Koh Y, Park J, Ahn KS, Kim I, Bang SM, Lee JH, Yoon SS, Soon Lee D, Yiul Lee Y, Park S, Kim BK.

Ann Hematol. 2009 Nov;88(11):1089-97. doi: 10.1007/s00277-009-0733-7. Epub 2009 Mar 19.

PMID:
19296110
16.

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M.

Cancer Chemother Pharmacol. 2010 Mar;65(4):679-86. doi: 10.1007/s00280-009-1073-y. Epub 2009 Jul 29.

PMID:
19639316
17.

Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.

Ferrara F, Izzo T, Criscuolo C, Riccardi C, Muccioli G, Viola A, Pane F, Palmieri S.

Biol Blood Marrow Transplant. 2010 Jul;16(7):1018-24. doi: 10.1016/j.bbmt.2010.02.011. Epub 2010 Feb 19.

18.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

PMID:
24981688
19.

Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.

Galmarini CM, Thomas X, Graham K, El Jafaari A, Cros E, Jordheim L, Mackey JR, Dumontet C.

Br J Haematol. 2003 Jul;122(1):53-60.

PMID:
12823345
20.

Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.

Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P; GOELAMS.

Am J Hematol. 2012 Dec;87(12):1052-6. doi: 10.1002/ajh.23311. Epub 2012 Aug 22.

Supplemental Content

Support Center